Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years

Hely, Mariese A., Morris, John G.L., Reid, Wayne G.J., Trafficante, Robert·2005·Movement Disorders

DOI 10.1002/mds.20324

Cited by (1,000)

Items 401–500 of 1,000

Prevalence of non-motor dysfunction among Parkinson's disease patients from a tertiary referral center in Mexico City
Mayela Rodríguez‐Violante, Amin Cervantes‐Arriaga, Alejandra Villar-Velarde, Teresa Corona · 2010 · Clinical Neurology and Neurosurgery
Parkinson’s disease and the bones
Alain Kaelin‐Lang, Markus Gnädinger, Hans-Ulrich Mellinghoff · 2011 · Swiss Medical Weekly
A clinical overview of non-motor symptoms in Parkinson's Disease.
Nicola Modugno, Francesco Lena, Francesca Di Biasio, Gloria Cerrone, Stefano A. Ruggieri, Francesco Fornai · 2013 · PubMed
Neuropsychologic assessment in collaborative Parkinson's disease research: A proposal from the National Institute of Neurological Disorders and Stroke Morris K. Udall Centers of Excellence for Parkinson's Disease Research at the University of Pennsylvania and the University of Washington
G. Stennis Watson, Brenna Cholerton, Rachel G. Gross, Daniel A. Weintraub, Cyrus P. Zabetian, John Q. Trojanowski, Thomas Jude Montine, Andrew D. Siderowf, James B. Leverenz · 2012 · Alzheimer s & Dementia
Increased levels of 5‐HT1A receptor binding in ventral visual pathways in Parkinson's disease
Philippe Huot, Tom H. Johnston, Naomi P. Visanji, Tayyeba Darr, Donna Pires, Lili‐Naz Hazrati, Jonathan M. Brotchie, Susan Helen Fox · 2012 · Movement Disorders
Evidence for Sprouting of Dopamine and Serotonin Axons in the Pallidum of Parkinsonian Monkeys
Dave Gagnon, Lara Eid, Dymka Coudé, Carl Whissel, Thérèse Di Paolo, André Parent, Martin Parent · 2018 · Frontiers in Neuroanatomy
5-HT2A blockade for dyskinesia and psychosis in Parkinson’s disease: is there a limit to the efficacy of this approach? A study in the MPTP-lesioned marmoset and a literature mini-review
Cynthia Kwan, Imane Frouni, Dominique Bédard, Stephen G. Nuara, Jim C. Gourdon, Adjia Hamadjida, Philippe Huot · 2018 · Experimental Brain Research
Randomized, controlled trial of fesoterodine fumarate for overactive bladder in Parkinson’s disease
Tarık Yonguç, Ertuğrul Şefik, İpek İnci, Özge Yılmaz Küsbeci, Serdar Çelik, Mehmet Erhan Aydin, Salih Polat · 2019 · World Journal of Urology
Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys
Nicolas Morin, Vincent A. Jourdain, Marc Morissette, Laurent Grégoire, Thérèse Di Paolo · 2014 · Neuropharmacology
RGFP109, a histone deacetylase inhibitor attenuates l-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: A proof-of-concept study
Tom H. Johnston, Philippe Huot, Sammie Damude, Susan Helen Fox, Steven W. Jones, James R. Rusche, Jonathan M. Brotchie · 2012 · Parkinsonism & Related Disorders
Genomic determinants of motor and cognitive outcomes in Parkinson’s disease
Sun Ju Chung, Sebastian M. Armasu, Joanna M. Biernacka, Kari J. Anderson, Timothy G. Lesnick, David N. Rider, Julie M. Cunningham, J. Eric Ahlskog, Roberta Frigerio, Demetrius M. Maraganore · 2012 · Parkinsonism & Related Disorders
Drug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?
Jean‐François Daneault, Benoit Carignan, Abbas F. Sadikot, Michel Panisset, Christian Duval · 2013 · BMC Medicine
Amantadine's role in the treatment of levodopa-induced dyskinesia
Robert L. Rodnitzky, Nandakumar S. Narayanan · 2013 · Neurology
Course, Prognosis, and Management of Psychosis in Parkinson's Disease:Are Current Treatments Really Effective?
Laura B. Zahodne, Hubert H. Fernandez · 2008 · CNS Spectrums
Effects of Acute Transcranial Direct Current Stimulation on Gait Kinematics of Individuals With Parkinson Disease
Débora Cristina Lima da Silva, Thiago Lemos, Arthur de Sá Ferreira, Carlos Henrique Ramos Horsczaruk, Carla Andressa Pedron, Érika C. Rodrigues, Laura Alice Santos de Oliveira · 2018 · Topics in Geriatric Rehabilitation
Mindfulness and Psychological Flexibility are Inversely Associated with Caregiver Burden in Parkinson’s Disease
Martin Klietz, Simon C. Drexel, Theresa Schnur, Florian Lange, Adrian Groh, Lejla Paracka, Stephan Greten, Dirk W. Dressler, Günter U. Höglinger, Florian Wegner · 2020 · Brain Sciences
Serotonin/dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesia: An update
Sara Corsi, Roberto Stancampiano, Manolo Carta · 2021 · Progress in brain research
Evaluation and management of the non-motor features of Parkinson’s disease
Steven Wishart, Graeme J.A. Macphee · 2010 · Therapeutic Advances in Chronic Disease
Chinese culture permeation in the treatment of Parkinson disease: a cross-sectional study in four regions of China
Zhenxin Zhang, Honglei Chen, Sheng-Di Chen, Ming Shao, Sheng-Gang Sun, Qiu-min QU, Bao-Rong Zhang, Yi-Ming Liu, Qun Xu, Xia Wan et al. · 2014 · BMC Research Notes
Indoor and outdoor falls in persons with Parkinson’s disease after 1 year follow-up study: differences and consequences
Tatjana M. Gazibara, Darija Kisić-Tepavčević, Marina V. Svetel, Aleksandra Tomić, Iva Stanković, Vladimir Kostić, Tatjana D. Pekmezovic · 2016 · Neurological Sciences
L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat
Philippe Huot, Tom H. Johnston, James B. Koprich, Maria Carmen Espinosa, M. Gabriela Reyes, Susan Helen Fox, Jonathan M. Brotchie · 2014 · Behavioural Pharmacology
Importance of Balance-Gait Disorder as a Risk Factor for Cognitive Impairment, Dementia and Related Non-Motor Symptoms in Parkinson’s Disease
David Gordon Lichter, Ralph Holmes Boring Benedict, Linda Ann Hershey · 2018 · Journal of Parkinson s Disease
Antidepressant Effects of Repetitive Transcranial Magnetic Stimulation Over Prefrontal Cortex of Parkinson's Disease Patients With Depression: A Meta-Analysis
Liang Zhou, Zhiwei Guo, Guoqiang Xing, Haitao Peng, Mengjie Cai, Huaping Chen, Morgan A. McClure, Lin He, Liangwen Xiong, Bin He et al. · 2019 · Frontiers in Psychiatry
Unraveling the threads of stability: A review of the neurophysiology of postural control in Parkinson's disease
Jasbir Bath, Doris D. Wang · 2024 · Neurotherapeutics
Visual feedback training using WII Fit improves balance in Parkinson's disease.
Tomasz Załęcki, Agnieszka Górecka-Mazur, Wojciech Pietraszko, Artur Dawid Surówka, Pawel Novak, Marek M Moskała, Anna Krygowska‐Wajs · 2013 · PubMed
Parkinson’s Disease Severity at 3 Years Can Be Predicted from Non-Motor Symptoms at Baseline
Alba Ayala, José Matías Triviño-Juárez, Maria João Forjaz, Carmen Rodríguez‐Blázquez, José-Manuel Rojo-Abuín, Pablo Martínez‐Martín · 2017 · Frontiers in Neurology
Depression Induced by Chronic Unpredictable Mild Stress Increases Susceptibility to Parkinson’s Disease in Mice via Neuroinflammation Mediated by P2X7 Receptor
Chao Ren, Ling-Xi Li, An-Qi Dong, Yuting Zhang, Hua Hu, Chengjie Mao, Fen Wang, Chun‐Feng Liu · 2021 · ACS Chemical Neuroscience
Inflammatory markers and depression in Parkinson’s disease: a systematic review
Luís Guilherme Ramanzini, Luís Fernando Muniz Camargo, Juliana Oliveira Freitas Silveira, Guilherme Vargas Bochi · 2022 · Neurological Sciences
Motor complications in patients form the German Competence Network on Parkinson's disease and the DRD3 Ser9Gly polymorphism
Sebastian Paus, Franziska Gadow, Michael Knapp, Christine Klein, Thomas Klockgether, Ullrich Wüllner · 2009 · Movement Disorders
An Update on Adenosine A2A Receptors as Drug Target in Parkinson's Disease
Antonio Vallano, Víctor Fernández‐Dueñas, Consuelo Pedrós, J.M. Arnau, Francisco Ciruela · 2011 · CNS & Neurological Disorders - Drug Targets
Two-Year Trajectory of Fall Risk in People With Parkinson Disease: A Latent Class Analysis
Serene Sulyn Paul, Anne Thackeray, Ryan P. Duncan, James T. Cavanaugh, Theresa D. Ellis, Gammon M. Earhart, Matthew P. Ford, Kenneth Bo Foreman, Leland E. Dibble · 2015 · Archives of Physical Medicine and Rehabilitation
The MPTP-lesioned marmoset model of Parkinson’s disease: proposed efficacy thresholds that may potentially predict successful clinical trial results
Francis Beaudry, Philippe Huot · 2020 · Journal of Neural Transmission
The Feasibility and Positive Effects of Wuqinxi Exercise on the Cognitive and Motor Functions of Patients with Parkinson’s Disease: A Pilot Study
Mengyue Shen, Yan‐Ling Pi, Zhenlan Li, Tao Song, Kuncheng Jie, Tian Wang, Wei Guo, Jie Zhuang, Zhen Wang · 2021 · Evidence-based Complementary and Alternative Medicine
The Factor Structure of the UPDRS as an Index of Disease Progression in Parkinson's Disease
Jonathan Evans, Sarah Mason, Caroline H. Williams‐Gray, Thomas Foltynie, Matthew W. B. Trotter, Roger A. Barker · 2011 · Journal of Parkinson s Disease
The effects of dopamine on digit span in Parkinson’s disease
Clara Warden, Jaclyn Joyce Hwang, Anisa J. Marshall, Michelle C. Fenesy, Kathleen L. Poston · 2016 · Journal of Clinical Movement Disorders
Depression in Parkinson's disease
Werner H Poewe · 2007 · Journal of Neurology
Nonmotor symptoms in Parkinson’s disease
Anna Hussl, Klaus Seppi, Werner H Poewe · 2013 · Expert Review of Neurotherapeutics
Building the bridge from bench to bedside
Jill U. Adams · 2008 · Nature Reviews Drug Discovery
Linalool, a Fragrance Compound in Plants, Protects Dopaminergic Neurons and Improves Motor Function and Skeletal Muscle Strength in Experimental Models of Parkinson’s Disease
Wan‐Hsuan Chang, Hung‐Te Hsu, Chih‐Cheng Lin, Li‐Mei An, Chien‐Hsing Lee, Horng‐Huey Ko, Chih‐Lung Lin, Yi‐Ching Lo · 2024 · International Journal of Molecular Sciences
Rapid assessment of postural instability in Parkinson’s disease (RAPID): a pilot study
Raymond K. Y. Chong, John C. Morgan, Shyamal H. Mehta, Iwona Pawlikowska, P. Hall, A. V. Ellis, A. D. Ibanez‐Wong, Gloria M Miller, K. Baugh, Kapil D. Sethi · 2010 · European Journal of Neurology
Effect of the glycine transporter 1 inhibitor ALX-5407 on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset
Imane Frouni, Sébastien Belliveau, Shawn P. Maddaford, Stephen G. Nuara, Jim C. Gourdon, Philippe Huot · 2021 · European Journal of Pharmacology
Beyond the Dopaminergic System: Lessons Learned from levodopa Resistant Symptoms in Parkinson's Disease
Angelo Antonini, Aron Emmi, Marta Campagnolo · 2023 · Movement Disorders Clinical Practice
Parkinsonism: heterogeneity of a common neurological syndrome
Georg Kägi · 2011 · Swiss Medical Weekly
Non-exercise physical activity attenuates motor symptoms in Parkinson disease independent from nigrostriatal degeneration
Jonathan Snider, Martijn L.T.M. Müller, Vikas Kotagal, Robert A. Koeppe, Peter J. H. Scott, Kirk A. Frey, Roger L. Albin, Nicolaas Ida Bohnen · 2015 · Parkinsonism & Related Disorders
Recurrent falls in Parkinson’s disease after one year of follow-up: A nested case-control study
Tatjana M. Gazibara, Darija Kisić-Tepavčević, Marina V. Svetel, Aleksandra Tomić, Iva Stanković, Vladimir Kostić, Tatjana D. Pekmezovic · 2016 · Archives of Gerontology and Geriatrics
Dopamine Reuptake Inhibitors in Parkinson’s Disease: A Review of Nonhuman Primate Studies and Clinical Trials
Philippe Huot, Susan Helen Fox, Jonathan M. Brotchie · 2016 · Journal of Pharmacology and Experimental Therapeutics
Depression in Parkinson’s Disease: The Contribution from Animal Studies
Jéssica Lopes Fontoura, Camila Baptista, Flávia de Brito Pedroso, José Augusto Pochapski, Edmar Miyoshi, Marcelo Machado Ferro · 2017 · Parkinson s Disease
Dopaminergic Effect on Non-Motor Symptoms in Late Stage Parkinson’s Disease
Kristina Rosqvist, Per Odin, Peter Hagell, Susanne Iwarsson, Maria H Nilsson, Alexander Storch · 2018 · Journal of Parkinson s Disease
Ondansetron, a highly selective 5-HT3 receptor antagonist, reduces L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease
Cynthia Kwan, Imane Frouni, Dominique Bédard, Adjia Hamadjida, Philippe Huot · 2020 · European Journal of Pharmacology
Pharmacological Treatment of Early Motor Manifestations of Parkinson Disease (PD)
Michelle Ann C. Sy, Hubert H. Fernandez · 2020 · Neurotherapeutics
Increased Mortality in Young-Onset Parkinson’s Disease
Eldbjørg Hustad, Tor Åge Myklebust, Sasha Gulati, Jan Olav Aasly · 2021 · Journal of Movement Disorders
Treatment options for non-motor symptoms in late-stage Parkinson's disease
Miguel M Coelho, Joaquim José Ferreira, Mário Miguel Rosa, Cristina Sampaio · 2008 · Expert Opinion on Pharmacotherapy
The cortical thickness correlates of clinical manifestations in the mid-stage sporadic Parkinson’s disease
Xia Deng, Chunyan Tang, Jie Zhang, Lei Zhu, Zunchun Xie, Honghan Gong, Xiang-Zuo Xiao, Renshi Xu · 2016 · Neuroscience Letters
Lessons learned from a large single center cohort of patients referred for DBS management
Benzi M. Kluger, Kelly D. Foote, Charles E. Jacobson, Michael S. Okun · 2010 · Parkinsonism & Related Disorders
Premotor Symptoms as Predictors of Outcome in Parkinsons Disease: A Case-Control Study
Yu-Hsuan Wu, Wei‐Ju Lee, Yi-Huei Chen, Ming‐Hong Chang, Ching‐Heng Lin · 2016 · PLoS ONE
Combined 5-HT2A and mGlu2 modulation for the treatment of dyskinesia and psychosis in Parkinson's disease
Cynthia Kwan, Imane Frouni, Stephen G. Nuara, Sébastien Belliveau, Woojin Kang, Adjia Hamadjida, Dominique Bédard, Francis Beaudry, Michel Panisset, Jim C. Gourdon et al. · 2021 · Neuropharmacology
Mechanisms of Antiparkinsonian Anticholinergic Therapy Revisited
Rodrigo Manuel Paz, Mario Gustavo Murer · 2021 · Neuroscience
Role of 5-HT1A Receptor in Vilazodone-Mediated Suppression of L-DOPA-Induced Dyskinesia and Increased Responsiveness to Cortical Input in Striatal Medium Spiny Neurons in an Animal Model of Parkinson’s Disease
Feras Altwal, Fernando E. Padovan‐Neto, Alexandra C. Ritger, Heinz Steiner, Anthony R. West · 2021 · Molecules
Effects of mind-body exercises on cognitive impairment in people with Parkinson's disease: A mini-review
Ting Zhang, Wei Liu, Song Gao · 2022 · Frontiers in Neurology
IN-HOME-PD Caregivers: The effects of a combined home visit and peer mentoring intervention for caregivers of homebound individuals with advanced Parkinson's disease
Jori Erin Fleisher, Madhuvanthi Suresh, Ellen C. Klostermann, Jeanette Lee, Serena Hess, Erica Myrick, Daniela Mitchem, Katheryn Woo, Brianna J. Sennott, Natalie P. Witek et al. · 2022 · Parkinsonism & Related Disorders
The treatment of early Parkinson's disease: levodopa rehabilitated
Annemarie M. M. Vlaar, A. Hovestadt, Teus van Laar, Bastiaan R. Bloem · 2011 · Practical Neurology
Cognitive decline tracks motor progression and not disease duration in Parkinson patients
Hubert H. Fernandez · 2008 · Neuropsychiatric Disease and Treatment
Effect of the selective 5-HT2A receptor antagonist EMD-281,014 on l-DOPA-induced abnormal involuntary movements in the 6-OHDA-lesioned rat
Imane Frouni, Cynthia Kwan, Dominique Bédard, Sébastien Belliveau, Élodie Bourgeois-Cayer, Fleur Gaudette, Francis Beaudry, Adjia Hamadjida, Philippe Huot · 2018 · Experimental Brain Research
Motor/Nonmotor Symptoms and Progression in Patients with Parkinson’s Disease: Prevalence and Risks in a Longitudinal Study
Asako Yoritaka, Yasushi Shimo, Taku Hatano, Nobutaka Hattori · 2020 · Parkinson s Disease
Rhinorrhea: A common nondopaminergic feature of Parkinson's disease
Kelvin L. Chou, Robert A. Koeppe, Nicolaas Ida Bohnen · 2010 · Movement Disorders
Impact of the Parkinson's disease medication protocol program on nurses' knowledge and management of Parkinson's disease medicines in acute and aged care settings
Lynn Chenoweth, June N. Sheriff, Larraine McAnally, Fiona Tait · 2012 · Nurse Education Today
mGlu5, Dopamine D2and Adenosine A2AReceptors in L-DOPA-induced Dyskinesias
Nicolas Morin, Marc Morissette, Laurent Grégoire, Thérèse Di Paolo · 2016 · Current Neuropharmacology
The management of psychosis in movement disorder patients
Kelvin L. Chou, Leora L. Borek, Joseph H. Friedman · 2007 · Expert Opinion on Pharmacotherapy
Levodopa treatment in Parkinson’s disease: earlier or later?
Federico Paolini Paoletti, Nicola Tambasco, Lucilla Parnetti · 2019 · Annals of Translational Medicine
Levodopa‐Induced Dyskinesias are Frequent and Impact Quality of Life in Parkinson's Disease: A 5‐Year Follow‐Up Study
Diego Santos‐García, Teresa de Deus Fonticoba, Carlos Cores Bartolomé, María José Feal Painceiras, María Cristina Íñiguez Alvarado, Lucía B. Samaniego, Antón López Maside, Silvia Jesús, Marina Cosgaya, Juan García Caldentey et al. · 2024 · Movement Disorders Clinical Practice
Mortality from Parkinson’s disease in China: Findings from a five-year follow up study in Shanghai
Gang Wang, Xinjian Li, Yisong Hu, Qi Cheng, Chunfang Wang, Qin Xiao, Jun Liu, Jianfang Ma, Haiyan Zhou, Jing Pan et al. · 2015 · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
Postural control of Parkinson’s disease: A visualized analysis based on Citespace knowledge graph
Yan Li, Jiejiao Zheng, Xie Wu, Wen Yuan Gao, Chan-Jing Liu · 2023 · Frontiers in Aging Neuroscience
Subjective cognitive decline in patients with Parkinson’s disease: an updated review
Juan Huang, Xingxing Yuan, Lin Chen, Binbin Hu, Lijuan Jiang, Ting Shi, Hui Wang, Wei Huang · 2023 · Frontiers in Aging Neuroscience
Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease
Jonathan Evans, Roger A. Barker · 2011 · Expert Opinion on Pharmacotherapy
Sleep disorders in Parkinson’s disease
Cynthia L. Comella · 2008 · Current Treatment Options in Neurology
Parkinson's disease: emerging pharmacotherapy
Karl Strecker, Johannes Schwarz · 2008 · Expert Opinion on Emerging Drugs
Pattern of Executive Impairment in Mild to Moderate Parkinson's Disease
Aleksandra Kudlicka, Linda Clare, John Vincent Hindle · 2013 · Dementia and Geriatric Cognitive Disorders
A comprehensive overview of the neuropsychiatry of Parkinson's disease: A review
Muhammad Adnan Khan, Syed A. Quadri, Hassaan Tohid · 2017 · Bulletin of the Menninger Clinic
Lipoic acid alleviates L‑DOPA‑induced dyskinesia in 6‑OHDA parkinsonian rats via anti‑oxidative stress
Su‑Fang Zhang, Chenglong Xie, Jingya Lin, Mei‑Hua Wang, Xijin Wang, Zhenguo Liu · 2017 · Molecular Medicine Reports
Can early dopamine transporter imaging serve as a predictor of Parkinson's disease progression and late motor complications?
Ruth Djaldetti, Amihai Rigbi, Lior Greenbaum, Johnathan Reiner, Mordechai Lorberboym · 2018 · Journal of the Neurological Sciences
Long term follow-up study of non-invasive brain stimulation (NBS) (rTMS and tDCS) in Parkinson’s disease (PD). Strong age-dependency in the effect of NBS
Judit Málly, Trevor W. Stone, Gabriella Sinkó, Noémi Geisz, Elek Dinya · 2018 · Brain Research Bulletin
Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmoset
Adjia Hamadjida, Stephen G. Nuara, Dominique Bédard, Imane Frouni, Cynthia Kwan, Jim C. Gourdon, Philippe Huot · 2018 · Naunyn-Schmiedeberg s Archives of Pharmacology
Global cognitive performance is associated with sleep efficiency measured by polysomnography in patients with Parkinson's disease
Emmanuelle Silva Tavares Sobreira, Manoel Alves Sobreira-Neto, Márcio Alexandre Pena-Pereira, Marcos Hortes Nisihara Chagas, Regina Maria França Fernandes, Álan Luiz Éckeli, Vítor Tumas · 2019 · Psychiatry and Clinical Neurosciences
The highly selective mGlu 2 receptor positive allosteric modulator LY‐487,379 alleviates l ‐DOPA‐induced dyskinesia in the 6‐OHDA‐lesioned rat model of Parkinson's disease
Adjia Hamadjida, Lamia Sid‐Otmane, Cynthia Kwan, Imane Frouni, Vaidehi Nafade, Dominique Bédard, Dave Gagnon, Marie‐Josée Wallman, Claude Rouillard, André Parent et al. · 2020 · European Journal of Neuroscience
Classical Parkinson disease versus Parkinson complex – Reflections against staging and in favour of heterogeneity
Gurutz Linazasoro · 2007 · European Journal of Neurology
Current Therapies and Drug Development Pipeline in Lewy Body Dementia: An Update
Steve MacDonald, Ayushi Samir Shah, Babak Tousi · 2022 · Drugs & Aging
Non-invasive brain stimulation for treating psychiatric symptoms in Parkinson’s disease: A systematic review and meta-analysis
Haibo Zheng, Bing Liu, Jing Shen, Feng Xie, Qiu-Ming Ji, Xinyue Zhu · 2022 · Journal of Clinical Neuroscience
Cognitive Effects of Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease with GBA1 Pathogenic Variants
Gian D. Pal, Daniel M. Corcos, Leo Verhagen Metman, Zvi H. Israel, Hagai Bergman, David Arkadir · 2023 · Movement Disorders
Physiotherapy in Parkinson's disease patients: Recommendations for clinical practice
Christoph Redecker, Anja Bilsing, Ilona Csóti, Wolfgang Fogel, Georg Ebersbach, Björn Hauptmann, Bernhard Hellwig, Martina Müngersdorf · 2014 · Basal Ganglia
Clinical problems in late-stage Parkinson’s disease
Oscar S. Gershanik · 2010 · Journal of Neurology
Validation and cross‐cultural adaptation of the Falls Efficacy Scale in patients with Parkinson's disease in S erbia
Tatjana M. Gazibara, Iva Stanković, Aleksandra Tomić, Marina V. Svetel, Darija Kisić-Tepavčević, Vladimir Kostić, Tatjana D. Pekmezovic · 2013 · Geriatrics and gerontology international/Geriatrics & gerontology international
Trajectories of recovery in depressed Parkinson's disease patients treated with paroxetine or venlafaxine
Martinus P. G. Broen, Albert F.G. Leentjens, Sebastian Köhler, Mark L. Kuijf, William Maffitt McDonald, I Richard · 2015 · Parkinsonism & Related Disorders
Management of patients with Parkinson disease
Ju Young Shin, Cristina C. Hendrix · 2013 · The Nurse Practitioner
DAT gene polymorphisms (rs28363170, rs393795) and levodopa-induced dyskinesias in Parkinson's disease
Carlo Purcaro, Nicola Vanacore, Federica Moret, Maria Elena Di Battista, Alfonso Rubino, Silvia Pierandrei, Marco Lucarelli, Giuseppe Meco, Francesco Fattapposta, Esterina Pascale · 2018 · Neuroscience Letters
Levodopa/Carbidopa Enteral Suspension: A Review in Advanced Parkinson’s Disease
Sheridan M. Hoy · 2019 · Drugs
Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update
Sohaila A. Alshimemeri, Susan Helen Fox, Naomi P. Visanji · 2020 · Expert Opinion on Emerging Drugs
The Effects of Withdrawal of Dopaminergic Medication in Nursing Home Patients With Advanced Parkinsonism
Winona Tse, Pasquale G. Frisina, Thomas D. Hälbig, Jean‐Michel Graciès, L LIANG, Chaim Y. Tarshish, Glenn Jay Lesser, Richard R. Neufeld, William C. Koller, Leslie S. Libow · 2008 · Journal of the American Medical Directors Association
L-DOPA-Induced Motor Impairment and Overexpression of Corticostriatal Synaptic Components Are Improved by the mGluR5 Antagonist MPEP in 6-OHDA-Lesioned Rats
Yixian Huang, Haiyang Shu, Li Li, Tili Zhen, Junyan Zhao, Xianju Zhou, Weifeng Luo · 2018 · ASN NEURO
Neuroprotective Effects of a GLP-2 Analogue in the MPTP Parkinson’s Disease Mouse Model
Zijuan Zhang, Hao Li, Ming Shi, Ziyang Yu, Simai Shao, Ye Yuan, Zhenqiang Zhang, Christian Hölscher · 2021 · Journal of Parkinson s Disease
Resource Utilization of Patients with Parkinson’s Disease in the Late Stages of the Disease in Germany: Data from the CLaSP Study
Christopher Kruse, Sabrina Kretschmer, Anna Luísa Lipinski, Malte Verheyen, David Mengel, Monika Balzer‐Geldsetzer, Stefan Lorenzl, Carmen Richinger, Christian Schmotz, Lars Tönges et al. · 2021 · PharmacoEconomics